Trxade Group, Inc. (NASDAQ:MEDS) to Post Q1 2022 Earnings of $0.02 Per Share, Taglich Brothers Forecasts

Share on StockTwits

Trxade Group, Inc. (NASDAQ:MEDS) – Taglich Brothers issued their Q1 2022 earnings estimates for shares of Trxade Group in a note issued to investors on Monday, April 5th. Taglich Brothers analyst H. Halpern anticipates that the company will post earnings per share of $0.02 for the quarter. Taglich Brothers also issued estimates for Trxade Group’s Q2 2022 earnings at $0.09 EPS, Q3 2022 earnings at $0.12 EPS, Q4 2022 earnings at $0.07 EPS and FY2022 earnings at $0.30 EPS.

Other equities analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of Trxade Group from a “hold” rating to a “sell” rating in a report on Wednesday, March 31st. Colliers Securities reissued a “buy” rating and issued a $10.00 target price on shares of Trxade Group in a research note on Tuesday, March 30th. Finally, Maxim Group assumed coverage on shares of Trxade Group in a research note on Friday, February 26th. They issued a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $10.81.

Shares of MEDS opened at $5.00 on Wednesday. The firm has a market cap of $40.47 million, a PE ratio of 166.67, a price-to-earnings-growth ratio of 0.83 and a beta of 1.42. The company’s fifty day moving average is $6.32 and its two-hundred day moving average is $5.75. Trxade Group has a fifty-two week low of $4.02 and a fifty-two week high of $8.25. The company has a quick ratio of 16.81, a current ratio of 19.89 and a debt-to-equity ratio of 0.02.

Trxade Group (NASDAQ:MEDS) last announced its quarterly earnings results on Sunday, March 28th. The company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.21). Trxade Group had a negative net margin of 4.28% and a negative return on equity of 8.28%.

Hedge funds have recently modified their holdings of the company. BlackRock Inc. raised its stake in shares of Trxade Group by 28.9% in the 3rd quarter. BlackRock Inc. now owns 10,426 shares of the company’s stock valued at $65,000 after acquiring an additional 2,336 shares during the period. Renaissance Technologies LLC purchased a new stake in Trxade Group during the 4th quarter worth $212,000. Finally, National Asset Management Inc. purchased a new stake in Trxade Group during the 4th quarter worth $454,000. 13.13% of the stock is currently owned by institutional investors and hedge funds.

Trxade Group Company Profile

Trxade Group, Inc, together with its subsidiaries, operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services.

Read More: How to Invest in the Dividend Aristocrat Index

Earnings History and Estimates for Trxade Group (NASDAQ:MEDS)

Receive News & Ratings for Trxade Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trxade Group and related companies with's FREE daily email newsletter.